Contact this trialFirst, we need to learn more about you.
Virus Therapy
Pembrolizumab + M032 for Glioblastoma
Recruiting1 awardPhase 1 & 2
Birmingham, Alabama
This trial is designed to confirm the safety and tolerability of Pembrolizumab when given with M032, an Oncolytic Herpes Simplex Virus that expresses IL-12. The Phase II portion of the trial will use a Recommended Phase 2 Dose of M032 (provided by the Phase I) when given with Pembrolizumab for recurrent malignant glioma.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service